The pipeline of anti-obesity medications (AOMs) is rapidly expanding, with more than 170 assets in development 1 — a surge driven by the success of incretin mimetics like semaglutide and tirzepatide. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results